The following amendment has been made to the ' Grant of Share Options' announcement released on 23 November 2023 at 07:00 under RNS No 3917U.

The sentence "All the Share Options granted one twelfth of the Share Options vest 3 months from the date of grant with one twelfth vesting quarterly after that, subject to the individuals remaining employed by the Company as Non-Executive Directors" has been removed and replaced with "The share option grant would vest 100% in 12 months from date of grant".

All other details remain unchanged.

The full amended text is shown below.

Renalytix plc

("Renalytix" or the "Company")

Grant of Share Options

LONDON and SALT LAKE CITY - November 23, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that the Board have granted options over a total of 380,000 ordinary shares of 0.25 pence each in the capital of the Company (the "Share Options") to the following individuals:

The Share Options, which have been issued in line with the Company's existing share option plan, have an exercise price of £0.245 per ordinary share, being the closing price of the shares on the 17 November 2023.  

The share option grant would vest 100% in 12 months from date of grant.

The issue of the Share Options are deemed to be related party transactions pursuant to AIM Rule 13 of the AIM Rules for Companies. The Company's directors (excluding those who are being awarded the Share Options) consider, having consulted with the Nominated Adviser, Stifel Nicolaus Europe Limited, that the terms of the related party transactions are fair and reasonable insofar as the shareholders of the Company are concerned.

For further information, please contact:

About Renalytix

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.